Lee, Se-Hoon

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1,180

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 893

Lung adenocarcinoma promotion by air pollutants

Hill, W., Lim, E. L., Weeden, C. E., Lee, C., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Evans, E. J., Moore, D. A., et al. (2023) · Nature

Air Quality and Health ImpactsCarcinogens and Genotoxicity Assessment

Cited by 808

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., et al. (2020) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 358

Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice

Lee, S.-H., Cho, S.-Y., Yoon, Y., Park, C., Sohn, J., Jeong, J.-J., Jeon, B.-N., Jang, M., An, C., Lee, S., et al. (2021) · Nature Microbiology

Gut microbiota and healthCancer Immunotherapy and Biomarkers

Cited by 325

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer

Park, S., Ock, C.-Y., Kim, H., Pereira, S., Park, S., Ma, M., Choi, S., Kim, S., Shin, S., Aum, B. J., et al. (2022) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersAI in cancer detection

Cited by 280

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis

Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., Kim, T.-Y., et al. (2011) · Breast Cancer Research

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 235

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim, Y., Lee, B., Shim, J. H., Lee, S.-H., Park, W.-Y., Choi, Y.-L., Sun, J.-M., Ahn, J. S., Ahn, M.-J., & Park, K. (2019) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 174

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis

Lee, J.-K., Hahn, S., Kim, D.-W., Suh, K. J., Keam, B., Kim, T. M., Lee, S.-H., & Heo, D. S. (2014) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 141

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 123

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

Keam, B., Kim, D.-W., Park, J. H., Lee, J.-O., Kim, T. M., Lee, S.-H., Chung, D. H., & Heo, D. S. (2014) · International Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 113

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

Lee, B., Lee, T., Lee, S.-H., Choi, Y.-L., & Han, J. (2016) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 78

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee, J. Y., Sun, J.-M., Lim, S. H., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H.-N., Ku, B. M., Koh, J., Bae, Y.-H., et al. (2016) · Clinical Cancer Research

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 36